Acucela, a Seattle-based clinical stage biotechnology company specialising in ophthalmic disease, has announced, as of December 27th, 2013, that it has been approved by the Tokyo Stock Exchange (TSE) and is planning to be listed on the TSE Mothers Exchange on February 13, 2014. The company was originally founded as a spin-out by ophthalmologist and current President & CEO, Dr. Ryo Kubota in September 2003. Founding of the company was supported by two Japanese companies and the University of Washington. The public share offering will be underwritten by Mitsubishi UFJ Morgan Stanley Securities.
Clinical stage ophthalmic company Acucela Inc., aims to raise $125M with Japanese IPO.
- by swdadmin